AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 23.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,711 shares of the company's stock after buying an additional 6,817 shares during the quarter. Sequoia Financial Advisors LLC's holdings in AstraZeneca were worth $2,625,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Banque Transatlantique SA acquired a new stake in shares of AstraZeneca in the fourth quarter valued at $26,000. Confluence Investment Management LLC purchased a new stake in shares of AstraZeneca during the first quarter worth $27,000. Mascagni Wealth Management Inc. acquired a new stake in shares of AstraZeneca in the fourth quarter valued at $29,000. FNY Investment Advisers LLC purchased a new position in AstraZeneca in the first quarter valued at $29,000. Finally, Highline Wealth Partners LLC grew its stake in AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after purchasing an additional 340 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas assumed coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has an average rating of "Moderate Buy" and an average target price of $85.00.

AstraZeneca Stock Performance

Shares of AZN traded down $0.43 during mid-day trading on Wednesday, reaching $71.03. 2,478,820 shares of the company's stock were exchanged, compared to its average volume of 5,392,212. The business's fifty day simple moving average is $70.72 and its 200-day simple moving average is $70.56. The stock has a market capitalization of $220.30 billion, a PE ratio of 28.53, a price-to-earnings-growth ratio of 1.28 and a beta of 0.37. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business's revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the company posted $2.06 earnings per share. On average, equities research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.